The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show. Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63% liver fat, 34% visceral fat and showed minimal lean mass change at the highest dose. The results demonstrate survodutide’s potential to… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the UK made headlines for both the investment it has attracted and… Read More
News round-up for 27 April – 1 May by Bruno Quinney, Content Team at DDW. This week, the UK has made headlines for both the investment it has attracted and the clinical trial reforms it has rolled out. Elsewhere, the world’s first antimalarial drug for newborns could soon address a critical unmet… Read More
Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana’s drug delivery technology is designed… Read More
A research team at the University of Dundee have been recognised for their work with industry partner, Boehringer Ingelheim, with the Biochemical Society’s 2026 Industry and Academic Collaboration Award. The award ‘recognises and promotes an outstanding individual or team who has made an inspirational contribution to the… Read More
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931. The therapy has been designed to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene… Read More
The US Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib for unresectable or metastatic non-small cell lung cancer (NSCLC). It is indicated for adult patients whose tumours have HER2 (ERBB2) mutations and who have received prior systemic therapy. … Read More
A new multinational clinical trial will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD). The EASi-KIDNEY trial will evaluate whether vicadrostat, also known as BI 690517, improves clinical outcomes when it is given in combination with existing treatments. Read More
Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More
Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the… Read More
CDR-Life has reached a development milestone with its antibody fragment-based drug candidate that could significantly slow down the progression of geographic atrophy (GA). Boehringer Ingelheim and CDR-Life entered a collaboration and licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate… Read More
New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The findings were presented at the 2023 American Diabetes Association’s… Read More
A partnership between RetinAI Medical and Boehringer Ingelheim aims to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, advanced form of age-related macular degeneration and a leading cause… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. ‘Teamwork makes the dream work’ this week, with the launch of… Read More
News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More
A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes. The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with… Read More
